{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:44:23Z","timestamp":1779921863550,"version":"3.53.1"},"reference-count":53,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.3892\/or.2016.5010","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T11:26:15Z","timestamp":1470741975000},"page":"2135-2141","source":"Crossref","is-referenced-by-count":22,"title":["MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells"],"prefix":"10.3892","volume":"36","author":[{"given":"Liang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Gui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"key20180107221229_b1-or-36-04-2135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"key20180107221229_b2-or-36-04-2135","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4103\/0366-6999.155100","article-title":"Low programmed cell death 5 expression is a prognostic factor in ovarian cancer","volume":"128","author":"Gao","year":"2015","journal-title":"Chin Med J"},{"key":"key20180107221229_b3-or-36-04-2135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-015-1231-z","article-title":"Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"key":"key20180107221229_b4-or-36-04-2135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-9966-31-38","article-title":"Circulating microRNAs in cancer: Origin, function and application","volume":"31","author":"Ma","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180107221229_b5-or-36-04-2135","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1007\/s13277-015-3605-x","article-title":"miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2","volume":"36","author":"Ma","year":"2015","journal-title":"Tumour Biol"},{"key":"key20180107221229_b6-or-36-04-2135","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/cas.12759","article-title":"Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer","volume":"106","author":"Yue","year":"2015","journal-title":"Cancer Sci"},{"key":"key20180107221229_b7-or-36-04-2135","first-page":"56","article-title":"miR-106a* inhibits the proliferation of esophageal carcinoma cells by targeting CDK2-associated Cullin 1 (CACUL1)","volume":"61","author":"Ma","year":"2015","journal-title":"Cell Mol Biol"},{"key":"key20180107221229_b8-or-36-04-2135","first-page":"1","article-title":"Up-regulated circulating miR-106a by DNA methylation promised a potential diagnostic and prognostic marker for gastric cancer","volume":"15","author":"Yuan","year":"2015","journal-title":"Anticancer Agents Med Chem"},{"key":"key20180107221229_b9-or-36-04-2135","first-page":"3827","article-title":"miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN","volume":"8","author":"Xie","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20180107221229_b10-or-36-04-2135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","article-title":"Inflammation and ovarian cancer","volume":"58","author":"Macci\u00f2","year":"2012","journal-title":"Cytokine"},{"key":"key20180107221229_b11-or-36-04-2135","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.2174\/138161212802002797","article-title":"Interleukin-6\/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer","volume":"18","author":"Dijkgraaf","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key20180107221229_b12-or-36-04-2135","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R","article-title":"Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer","volume":"73","author":"Plante","year":"1994","journal-title":"Cancer"},{"key":"key20180107221229_b13-or-36-04-2135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bjc.1995.71","article-title":"Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer","volume":"71","author":"Scambia","year":"1995","journal-title":"Br J Cancer"},{"key":"key20180107221229_b14-or-36-04-2135","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-06-0861","article-title":"Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer","volume":"12","author":"Duan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107221229_b15-or-36-04-2135","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"key20180107221229_b16-or-36-04-2135","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","article-title":"Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma","volume":"15","author":"Shinriki","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107221229_b17-or-36-04-2135","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"key20180107221229_b18-or-36-04-2135","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20180107221229_b19-or-36-04-2135","doi-asserted-by":"crossref","first-page":"e0118080","DOI":"10.1371\/journal.pone.0118080","article-title":"Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer","volume":"10","author":"Isobe","year":"2015","journal-title":"PLoS One"},{"key":"key20180107221229_b20-or-36-04-2135","doi-asserted-by":"crossref","first-page":"e102436","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS One"},{"key":"key20180107221229_b21-or-36-04-2135","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","article-title":"Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia","volume":"31","author":"Ando","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107221229_b22-or-36-04-2135","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1200\/JCO.2012.48.4147","article-title":"Assessment of tocilizumab in the treatment of cancer cachexia","volume":"31","author":"Berti","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107221229_b23-or-36-04-2135","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jpainsymman.2013.01.009","article-title":"Favorable responses to tocilizumab in two patients with cancer-related cachexia","volume":"46","author":"Hirata","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"key20180107221229_b24-or-36-04-2135","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2015.3019","article-title":"Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells","volume":"9","author":"Kim","year":"2015","journal-title":"Oncol Lett"},{"key":"key20180107221229_b25-or-36-04-2135","first-page":"649086","article-title":"Severe pulmonary suppuration with infection-induced systemic inflammatory response syndrome following tongue cancer surgery in a patient undergoing tocilizumab therapy for rheumatoid arthritis","volume":"2014","author":"Yamagata","year":"2014","journal-title":"Case Rep Dent"},{"key":"key20180107221229_b26-or-36-04-2135","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1158\/0008-5472.CAN-06-0800","article-title":"MicroRNA-cancer connection: The beginning of a new tale","volume":"66","author":"Calin","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107221229_b27-or-36-04-2135","article-title":"MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells","author":"Chen","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180107221229_b28-or-36-04-2135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/pgs.15.166","article-title":"MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis","volume":"17","author":"Chen","year":"2016","journal-title":"Pharmacogenomics"},{"key":"key20180107221229_b29-or-36-04-2135","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1007\/s13277-015-4558-9","article-title":"MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1","volume":"37","author":"Fan","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180107221229_b30-or-36-04-2135","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1007\/s13277-015-4507-7","article-title":"MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS","volume":"37","author":"Fu","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180107221229_b31-or-36-04-2135","first-page":"1624","article-title":"Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3\/DDP cells","volume":"35","author":"Guo","year":"2015","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"key20180107221229_b32-or-36-04-2135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-23730-5_8","article-title":"microRNA and ovarian cancer","volume":"889","author":"Langhe","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"key20180107221229_b33-or-36-04-2135","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1007\/s13277-015-3191-y","article-title":"Serum microRNA-145 as a novel biomarker in human ovarian cancer","volume":"36","author":"Liang","year":"2015","journal-title":"Tumour Biol"},{"key":"key20180107221229_b34-or-36-04-2135","first-page":"10605","article-title":"MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1\/2 inactivation by targeting epidermal growth factor receptor","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20180107221229_b35-or-36-04-2135","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3892\/ol.2015.3012","article-title":"microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells","volume":"9","author":"Luo","year":"2015","journal-title":"Oncol Lett"},{"key":"key20180107221229_b36-or-36-04-2135","first-page":"328","article-title":"MicroRNA: A new and promising potential biomarker for diagnosis and prognosis of ovarian cancer","volume":"12","author":"Pal","year":"2015","journal-title":"Cancer Biol Med"},{"issue":"Suppl 5","key":"key20180107221229_b37-or-36-04-2135","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2105-16-S5-S5","article-title":"An integrated network of microRNA and gene expression in ovarian cancer","volume":"16","author":"Quitadamo","year":"2015","journal-title":"BMC Bioinformatics"},{"key":"key20180107221229_b38-or-36-04-2135","first-page":"16","article-title":"DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer","volume":"62","author":"Shariati-Kohbanani","year":"2016","journal-title":"Cell Mol Biol"},{"key":"key20180107221229_b39-or-36-04-2135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13048-015-0207-6","article-title":"MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1","volume":"8","author":"Sun","year":"2015","journal-title":"J Ovarian Res"},{"key":"key20180107221229_b40-or-36-04-2135","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.4103\/0366-6999.171459","article-title":"Research progress of microRNA in early detection of ovarian cancer","volume":"128","author":"Wang","year":"2015","journal-title":"Chin Med J"},{"key":"key20180107221229_b41-or-36-04-2135","doi-asserted-by":"crossref","DOI":"10.1007\/s13277-016-4944-y","article-title":"MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1","author":"Wu","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180107221229_b42-or-36-04-2135","first-page":"16","article-title":"MicroRNA signatures of platinum-resistance in ovarian cancer","volume":"36","author":"Ying","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"key":"key20180107221229_b43-or-36-04-2135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.yexmp.2012.11.002","article-title":"miR-106a overexpression and pRB downregulation in sporadic colorectal cancer","volume":"94","author":"Catela Ivkovic","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"key20180107221229_b44-or-36-04-2135","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/gcc.20580","article-title":"Deregulated expression of miR-106a predicts survival in human colon cancer patients","volume":"47","author":"D\u00edaz","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180107221229_b45-or-36-04-2135","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/abbs\/gmt106","article-title":"miR-106a confers cisplatin resistance by regulating PTEN\/Akt pathway in gastric cancer cells","volume":"45","author":"Fang","year":"2013","journal-title":"Acta Biochim Biophys Sin"},{"key":"key20180107221229_b46-or-36-04-2135","first-page":"13096","article-title":"Diagnostic significance of miR-106a in gastric cancer","volume":"8","author":"Hou","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20180107221229_b47-or-36-04-2135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.2013.305","article-title":"Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer","volume":"109","author":"Huh","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180107221229_b48-or-36-04-2135","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/1055-9965.EPI-13-0512","article-title":"Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test","volume":"22","author":"Koga","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107221229_b49-or-36-04-2135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.febslet.2014.01.007","article-title":"Upregulated miR-106a plays an oncogenic role in pancreatic cancer","volume":"588","author":"Li","year":"2014","journal-title":"FEBS Lett"},{"key":"key20180107221229_b50-or-36-04-2135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11596-013-1160-5","article-title":"MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells","volume":"33","author":"Rao","year":"2013","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"key20180107221229_b51-or-36-04-2135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/1471-2407-12-505","article-title":"Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer","volume":"12","author":"Schee","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107221229_b52-or-36-04-2135","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mc.21899","article-title":"miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS","volume":"52","author":"Wang","year":"2013","journal-title":"Mol Carcinog"},{"key":"key20180107221229_b53-or-36-04-2135","first-page":"354","article-title":"Expression of plasma miR-106a in colorectal cancer and its clinical significance","volume":"34","author":"Zhang","year":"2014","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2016.5010\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T22:14:24Z","timestamp":1515363264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2016.5010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,8,9]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.3892\/or.2016.5010"],"URL":"https:\/\/doi.org\/10.3892\/or.2016.5010","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}